Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

Hidradenitis Suppurativa Clinical Trial

Official title: Exploratory Trial of Ruxolitinib 1.5% Cream for the Treatment of Early Stage Hidradenitis Suppurativa

Status Recruiting

Clinical Trial Summary

Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: - Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. - Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.

Clinical Trial Description

The primary efficacy measure is the proportion of participants that achieve HiSCR at Week 16 with topical ruxolitinib 1.5% cream as compared to Week 0. The HiSCR is defined as an at least a 50% reduction in the total abscess and inflammatory nodule count (AN count) for all study body sites with no increase in abscess count and no increase in draining fistula count relative to Baseline. The primary efficacy analysis will be carried out on all participants who complete 16 weeks of treatment. The research study consists of an 8 week screening with 16 weeks open-label portion. ;

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa

• NCT number: NCT04414514
• Study type: Interventional
• Source: Milton S. Hershey Medical Center
• Contact: Joslyn Kirby, MD
• Phone: 717-531-1513
• Email: jkirby1@pennstatehealth.psu.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: October 13, 2022
• Completion date: January 2025